Paul J. Ross

Active 1982–2025

75
Papers
19,983
Citations
55
h-index
74
i10-index

Citations

Citations per year for Paul J. Ross1939: 1 citations1990: 2 citations1992: 1 citations1993: 1 citations1994: 3 citations1995: 1 citations1996: 3 citations1997: 5 citations1998: 11 citations1999: 22 citations2000: 33 citations2001: 18 citations2002: 20 citations2003: 30 citations2004: 25 citations2005: 41 citations2006: 44 citations2007: 50 citations2008: 61 citations2009: 49 citations2010: 57 citations2011: 40 citations2012: 40 citations2013: 40 citations2014: 50 citations2015: 63 citations2016: 79 citations2017: 185 citations2018: 242 citations2019: 859 citations2020: 1,047 citations2021: 958 citations2022: 749 citations2023: 509 citations2024: 845 citations2025: 349 citations2026: 3 citations1940–1989: no citations, so these years are not shown1991: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,859 citing papers, 18.8% of this breakdownChina: 1,315 citing papers, 13.3% of this breakdownItaly: 663 citing papers, 6.7% of this breakdownUnited Kingdom: 654 citing papers, 6.6% of this breakdownGermany: 641 citing papers, 6.5% of this breakdownJapan: 630 citing papers, 6.4% of this breakdownFrance: 433 citing papers, 4.4% of this breakdownSpain: 382 citing papers, 3.8% of this breakdownSouth Korea: 293 citing papers, 3% of this breakdownNetherlands: 276 citing papers, 2.8% of this breakdownCanada: 270 citing papers, 2.7% of this breakdownTaiwan: 200 citing papers, 2% of this breakdown
0%18.8%Other 23%

Fields

  • Medicine80%
  • Biochemistry, Genetics and Molecular Biology12.5%
  • Immunology and Microbiology2.7%
  • Materials Science1.1%
  • Engineering1.1%
  • Agricultural and Biological Sciences0.7%
  • Other1.9%

Topics

  • Hepatocellular Carcinoma Treatment and Prognosis9.2%
  • Pancreatic and Hepatic Oncology Research7.9%
  • Cholangiocarcinoma and Gallbladder Cancer Studies7.7%
  • Cancer Immunotherapy and Biomarkers3.5%
  • Cancer Mechanisms and Therapy2.9%
  • Gallbladder and Bile Duct Disorders2.9%
  • Other65.9%

Coauthors

All papers

Open in search
  1. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2016 cited by 3,663

  2. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pascal Hammel, Thilo Hackert, Richard Jackson, Markus W. Büchler - The Lancet 2017 cited by 1,928

  3. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Helen Morement, Oscar S.H. Chan, C. Rees, Ma Yt, Tamas Hickish, Stephen Falk, Meg Finch-Jones, Ian Pope, Pippa Corrie, Tom Crosby, S. Sothi, K Sharkland, Douglas Adamson, Lucy Wall, JEFF EVANS, John Dent, U. Hombaiah, Chinenye Iwuji, Alan Anthoney, John Bridgewater, David Cunningham, Roopinder Gillmore, Paul J. Ross, S. Slater, Harpreet Wasan, Jill Waters, Juan W. Valle, Daniel H. Palmer, Hafiz Malik, John P. Neoptolemos, Olusola Olusesan Faluyi, Kate Sumpter, U. Dernedde, S Maduhusudan, G. Cogill, Caroline Archer, Timothy Iveson, Jonathan Wadsley, Suzanne Darby, Mike Peterson, AA Mukhtar, JG Thorpe, Adrian C Bateman, D. Tsang, S. Cummins, L. Nolan, Éric Beaumont, Rajendra Prasad, D. Mirza, Deborah Stocken, Raaj Praseedom, Brian R Davidson, James Raftery, Shihua Zhu, James Garden, C Stubbs, Fareeda Y. Coxon - The Lancet Oncology 2019 cited by 1,228

  4. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 749

  5. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jen‐Shi Chen, Yeu‐Chin Chen, Hye Jin Choi, Ik Joo Chung, Vincent Chung, Tibor Csőszi, Antonio Cubillo, Linda C. DeMarco, Maike de Wit, Tomislav Dragovich, W. Jeff Edenfield, Luis Fein, Fábio Franke, Martin Fuchs, Vega Gonzales-Cruz, Alberto Gozza, Rivera Herrero Fernando, Rosario Vincenzo Iaffaioli, Jitka Jakesova, Zsuzsanna Kahán, Misagh Karimi, Jun Suk Kim, Ernesto Korbenfeld, István Láng, Fa-Chyi Lee, Kuan‐Der Lee, Lara Lipton, Wen Wee, László Mangel, Raul Mena, Daniel H. Palmer, Shubham Pant, Joon Oh Park, Paolo Piacentini, Uwe Pelzer, Javier Gállego, Cooray Prasad, Kun‐Ming Rau, Jean‐Luc Raoul, Donald Richards, Paul J. Ross, Luís Alberto Schlittler, Martin Šmakal, V. Stahalova, Cora N. Sternberg, Thomas Seufferlein, Niall C. Tebbutt, J. Vinholes, Raymond Wadlow, Milkos Wenczl, Mark Wong - The Lancet 2015 cited by 1,200

  6. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christoph Springfeld, Christine Tjaden, Thilo Hackert, Markus W. Büchler, John P. Neoptolemos - ˜The œLancet. Gastroenterology & hepatology 2022 cited by 325

  7. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2017 cited by 497

  8. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Charlotte Rawcliffe, Gemma Nanson, John P. Neoptolemos - The Lancet Oncology 2014 cited by 374

  9. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David Borg, Sharmila Sothi, Pascal Hammel, Markus M. Lerch, Julia Mayerle, Christine Tjaden, Oliver Strobel, Thilo Hackert, Markus W. Büchler, John P. Neoptolemos, for the European Study Group for Pancreatic Cancer - JAMA Surgery 2019 cited by 273

  10. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, N. Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F.A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri - Nature Medicine 2023 cited by 84

  11. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew Burge, Sumitra Ananda, Muhammad A. Khattak, Bruce Colwell, Félix Couture, Brandon M. Meyers, Kathryn Towns, Michael B. Sawyer, Lucas Sidéris, Rui‐Hua Xu, Wei Wang, Hongming Pan, Per Pfeiffer, Lars Henrik Jensen, Camilla Qvortrup, Sebastian Stintzing, Dirk Arnold, Sylvie Lorenzen, Stefan Kubicka, Reinhard Depenbusch, Maria Passhak, Ravit Geva, Ayala Hubert, Einat Shacham‐Shmueli, Gleb Kornev, Akihito Kawazoe, Toshiki Masuishi, Atsuo Takashima, Hiroki Hara, Hisato Kawakami, Nozomu Machida, Kentaro Yamazaki, Hisateru Yasui, Akihito Tsuji, Taito Esaki, Kensei Yamaguchi, Tae‐You Kim, Joong Bae Ahn, Myung Ah Lee, Tae Won Kim, Joon Oh Park, Soo Hyun Lee, Р. В. Орлова, V. O. Sarzhevskiy, Marina Sekacheva, S. Tjulandin, Oksana Shirokova, A.I. Iskhakova Iskhakova, A. A. Lebedinets, Paula Jiménez Fonseca, F. Rivera Herrero, Elena Elez Fernandez, Pilar Alfonso, M.J. Gómez Reina, Kun‐Huei Yeh, Hao‐Wei Teng, Tsai Sheng Yang, Hwei‐Ming Wang, Yu‐Min Yeh, Mustafa Özgüroğlu, Mahmut Gumus, Şuayib Yalçın, Bülent Erdoğan, Umut Demırcı, Pınar Gürsoy, Hakan Harputluoğlu, Atakan Demir, Kai‐Keen Shiu, Ewan Brown, Paul J. Ross and 13 more - Journal of Clinical Oncology 2024 cited by 77

  12. SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , , - Journal of Clinical Oncology 2014 cited by 577

  13. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 94

  14. Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Liver Cancer 2022 cited by 78

  15. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 280

  16. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Chan Ton, Charles Wilson, C. Lowdell, Charlotte Rees, Christopher Baughan, Clare Barlow, Colin Purcell, David Smith, David Tsang, Ewan Brown, Georgina Walker, Hassan Malik, Iain Cameron, Luke Nolan, Marcia Hall, Marjorie Tomlinson, Mark Hill, Mark Peterson, Meg Finch-Jones, Nagappan Kumar, N D Karanjia, Nasim Ali, Nigel Heaton, Nua Chan Ton, Paul J. Ross, Raaj Praseedom, Robert Thomas, Sally Clive, Sarah Slater, Sarah Smith, Satvinder Mudan, Satya Bhattacharya, Sharadah Essapen, Sherif Raouf, Stephen W. Fenwick, Susan Cleator, Tom Diamond, Vanessa Potter - The Lancet Oncology 2020 cited by 239

  17. Guidance on the management of diarrhoea during cancer chemotherapy

    Authors: , , , , , , , , , , , , - The Lancet Oncology 2014 cited by 255

  18. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

    Authors: , , , , , , , - British Journal of Cancer 2004 cited by 477

  19. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials

    Authors: , , , , , , , , , - JNCI Journal of the National Cancer Institute 2019 cited by 165

  20. The role of the PI3K pathway in colorectal cancer

    Authors: , , , - Critical Reviews in Oncology/Hematology 2014 cited by 127

  21. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer

    Authors: , , , , , , , , , , , , - European Radiology 2014 cited by 226

  22. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joanne Hornbuckle, F. Lofts, Sarah Lowndes, Astrid Mayer, Matthew S. Metcalfe, Gary Middleton, Jamie Mills, Amir Montazeri, R. Muirhead, Andreas Polychronis, Colin Purcell, Paul J. Ross, Ricky A. Sharma, Liz Sherwin, David Smith, Rubin Soomal, Daniel Swinson, Axel Walther, Harpreet Wasan, Andrew Weaver, Charles Wilson, Greg Wilson, Pradip Amin, Bruna Angelelli, Jacques Balosso, Alex Beny, Daniel Bloomgarden, Evelyn Boucher, Michael D. Brown, Harald-Robert Bruch, James Bui, Matthew Burge, Giuseppe Cardaci, James Carlisle, Seungjean Chai, Yi‐Jen Chen, P. Chevallier, Michael Chuong, Stephen Clarke, Andrew L. Coveler, M Craninx, Thierry Delanoit, Amélie Deleporte, Paul Eliadis, Francis Facchini, Thomas W. Ferguson, Michel Ferrante, Michael Findlay, Gary Frenette, Jacob Frick, Vinod Ganju, Michael Garofalo, Karen Geboes, Gerald Gehbauer, Benjamin George, Ravit Geva, Peter Gibbs, Melita A. Gordon, Kate Gregory, Seza A. Güleç, James Hannigan, Guy van Hazel, Norman Heching, Volker Heinemann, Thomas Helmberger, Alain Hendlisz, Koen Hendrickx, Matthew P. Holtzman, Richard Isaacs, Christopher Jackson and 156 more - The Lancet Oncology 2017 cited by 398

  23. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Hepatology 2016 cited by 127

  24. Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2024 cited by 24